# Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer

> **NCT01139138** · PHASE1,PHASE2 · COMPLETED · sponsor: **The Queen Elizabeth Hospital** · enrollment: 49 (actual)

## Conditions studied

- Colorectal Cancer
- Colorectal Carcinoma
- Colorectal Tumors
- Neoplasms, Colorectal

## Interventions

- **DRUG:** Panitumumab
- **DRUG:** Irinotecan
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01139138
- **Lead sponsor:** The Queen Elizabeth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2015-08
- **Final completion:** 2017-06
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2017-11-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01139138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01139138, "Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01139138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*